Dear OMIC Insureds:

We are pleased to announce the release of a consent form for FDA-approved IZERVAY™ (Avacincaptad pegol) Treatment for Geographic Atrophy, a form of Dry Age-Related Macular Degeneration.

Additionally, The Intravitreal Injection of Eylea®HD 8mg (aflibercept) form is now available.

If you have questions regarding this information, please contact us. Remember that you may contact the Risk Management Hotline for confidential assistance at riskmanagement@omic.com or call the Risk Management Hotline at 1-800-562-6642 and choose option 4.

Sincerely,

Linda D. Harrison, PhD
Vice President, OMIC Risk Management

CONFIDENTIALITY NOTICE: This correspondence is intended only for the person or entity to which it is addressed and may contain information that is privileged, confidential or otherwise protected from disclosure. Dissemination, distribution or copying of this e-mail or the information herein by anyone other than the intended recipient, or an employee or agent responsible for delivering the message to the intended recipient, is prohibited. If you have received this e-mail in error, please notify us at riskmanagement@omic.com and destroy the original message and all copies.
______________________________________________